
Novartis CEO To Step Down; DSM To Close Netherlands Facility; And More.

Novartis CEO To Step Down; DSM To Close Netherlands Facility; And More.

New York Governor Wants Stricter Limits On Pharmaceutical Marketing; And More.

The Director-General of the European Generic medicines Association has reiterated the group's Vision 2015 plan.

Two US senators have introduced the Nanotechnology Safety Act of 2010, which would establish a program within the US Food and Drug Administration to assess the health and safety implications of nanotechnology in everyday products.

Keiji Fukuda, special adviser on pandemic influenza to the World Health Organization's (WHO) director-general, told a hearing at the Council of Europe that WHO's response to the influenza (H1N1) pandemic was not improperly influenced by the pharmaceutical industry.

The European Medicines Agency has launched a public consultation on its Road Map to 2015, a strategic vision that lays out the agency's priorities for the next five years.

Lonza Group (Basel) plans to reinforce its presence in Asia, including its platform in Nansha, China, and to close its Conshohocken (Riverside), Pennsylvania; Shawinigan, Canada; and Wokingham, United Kingdom, sites in 2010.

FDA Issues Warning Letter To McNeil Healthcare; Charles River Laboratories Will Suspend Operations At Massachusetts Facility.

FDA Thanks Healthcare Workers For H1N1 Response; And More.

The EU's Commissioner-designate for Health and Consumer Policy, John Dalli, said that he is looking forward to the challenge of integrating the pharmaceutical area into public health as part of his role.

McNeil Consumer Healthcare is voluntarily recalling certain lots of over-the-counter products in the Americas, the United Arab Emirates, and Fiji.

Could flexible manufacturing change the standards for biopharmaceutical production? To find out, Equipment and Processing Report talked to James Robinson, vice-president of technical and quality operations at biotechnology company Novavax (Rockville, MD).

The authors sought to improve the productivity of protein synthesis by using a highly active cell-free extract from Escherichia coli and by optimizing buffer conditions and shaking conditions.

The United States Pharmacopeial Convention is recalling USP 33?NF 28.

Many life-sciences companies are likely to execute an acquisition in the next 12-24 months, according to a survey by Ernst & Young.

The European Commission has asked certain pharmaceutical companies to submit copies of their patent-settlement agreements.

Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for a H1N1 vaccine.

On Jan. 4, 2010, Novartis (Basel) and Nestlé began completing their 2008 agreement, under which Novartis will acquire Nestlé's remaining 52% stake in eye-care company Alcon (Hünenberg, Switzerland).

The US Food and Drug Administration released a warning to the public on Dec. 29, 2009 about criminals posing as FDA special agents and other law enforcement personnel as part of an international extortion scam.

Bioject Medical Technologies establishes alliance with MPI Research; Biogen Idec CEO to retire; And More.

Microelectronics offers "striking opportunities" for advancing biomedical research and creating new markets for the medical sciences industry.

This study used biological indicators containing Geobacillus stearothermophilus spores and a new technology to continuously monitor incubated BIs and record nonsterile results.

A comprehensive book about mass transfer benefits from the author's personal touch.

The authors describe the implementation of an on-line particle-size analyzer on an active pharmaceutical ingredient milling operation at a commercial site.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.

Directors and staff miss the mark when it comes to following procedures.

BioNanomatrix (Philadelphia) names Edward Erickson president and CEO; and More.

Hospira, a specialty pharmaceutical company, has agreed to acquire Orchid Chemicals' Pharmaceuticals for $400 million.

Merck & Co. Acquires Avecia Biologics; Ambrilia Biopharma Closes Manufacturing Facility; And More.

Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO).